GRC 65327
Alternative Names: GRC-65327Latest Information Update: 04 Jul 2025
At a glance
- Originator Ichnos Glenmark Innovation
- Developer Ichnos Glenmark Innovation; National Cancer Institute (USA)
- Class Antineoplastics; Small molecules
- Mechanism of Action CBLB protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Triple negative breast cancer
Most Recent Events
- 25 Apr 2025 Pharmacodynamics, adverse events and pharmacokinectics data from preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025) .
- 30 Sep 2024 Ichnos Glenmark Innovation entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute on evaluating GRC 65327
- 30 Sep 2024 Preclinical trials in Triple-negative-breast-cancer in USA (PO)